Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Cardiff Oncology and Nektar Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $508,000.00 | 159.27 | -$45.85 million | ($0.60) | -1.73 |
| Nektar Therapeutics | $55.23 million | 24.63 | -$164.08 million | ($6.70) | -5.95 |
Profitability
This table compares Cardiff Oncology and Nektar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
| Nektar Therapeutics | -287.84% | -37.87% | -25.67% |
Analyst Ratings
This is a breakdown of recent recommendations for Cardiff Oncology and Nektar Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
| Nektar Therapeutics | 1 | 4 | 10 | 1 | 2.69 |
Cardiff Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 621.15%. Nektar Therapeutics has a consensus target price of $130.67, suggesting a potential upside of 227.98%. Given Cardiff Oncology’s higher possible upside, equities analysts plainly believe Cardiff Oncology is more favorable than Nektar Therapeutics.
Insider and Institutional Ownership
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Cardiff Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Summary
Nektar Therapeutics beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
